Background: In recent years, the number of patients with nontuberculous mycobacteria (NTM) infections caused by invasive procedures such as cosmetic surgery has been increasing. However, treating NTM infections presents significant challenges, with no standardized diagnostic or treatment guidelines currently available.
Methods: This study included 10 patients diagnosed with skin and soft tissue NTM infections following cosmetic surgery. Each patient underwent surgical treatment, followed by PDT after debridement. PDT was performed using topical 20% 5-aminolevulinic acid (ALA, 2 mL: 10 mg) applied to the wound periphery (2 cm margin), followed by a 3-hour incubation under light occlusion and activation with a 635 nm diode laser at an energy density of 120 J/cm². Exposure durations were dynamically adjusted (20-40 minutes) based on real-time pain tolerance. Weekly PDT sessions were administered, with total treatment duration individualized according to wound healing progression. Post-procedural pain was assessed using the Facial Expression Pain Scale (FEPS) and managed through a tiered protocol: ice compression for mild-to-moderate pain (FEPS 2-4) and NSAIDs/opioids for severe pain (FEPS >4). Antibiotics were selected based on the results of drug susceptibility testing.
Results: All ten patients achieved clinical cure, with a notable reduction in the duration of therapy. All patients were followed for over six months without recurrence of infection. Post-PDT pain was universally in all patients, with FEPS scores ranging from 2 to 7, and managed effectively by the final treatment. Transient adverse events included erythema (n=10) and pruritus (n=2), resolving spontaneously within 48 hours. No chronic complications were observed.
Conclusion: The combination of surgical intervention and PDT, along with appropriate antibiotic therapy, is a safe and effective approach for treating skin and soft tissue NTM infections after cosmetic surgery.
Methods: PDT was performed using topical 20% ALA (10 mg/session) applied to the wound periphery (2 cm margin), followed by 3-hour occlusion and 635 nm laser irradiation (120 J/cm²; XD-635AB). Exposure durations were adjusted dynamically (20-40 minutes) based on real-time pain tolerance. Weekly sessions were administered until wound resolution. Pain severity (FEPS) was managed via a tiered protocol: ice/NSAIDs for scores 2-4 and opioids for scores >4. PDT was performed using 20% 5-ALA activated by a 635 nm laser with a light dose of 120 J/cm².
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.pdpdt.2025.104545 | DOI Listing |
Ther Adv Respir Dis
March 2025
Department of Medicine, National Jewish Health, Denver, CO, USA.
Nontuberculous mycobacteria (NTM) are ubiquitous, opportunistic pathogens that can cause lung disease in people with non-cystic fibrosis bronchiectasis (NCFB) and cystic fibrosis (CF). The incidence of NTM pulmonary infections and lung disease has continued to increase worldwide over the last decade among both groups. Notably, women with NCFB NTM pulmonary disease (NTM-PD) bear a disproportionate burden with NTM rates increasing in this population as well as having consistently higher incidence of NTM-PD compared to men.
View Article and Find Full Text PDFPLoS One
March 2025
Department of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Background: Routine screening for nontuberculous mycobacterial (NTM) lung disease is dependent on sputum cultures. This is particularly challenging in the cystic fibrosis (CF) population due to reduced sputum production and low culture sensitivity. Biomarkers of infection that do not rely on sputum may lead to earlier diagnosis, but validation trials require a unique prospective design.
View Article and Find Full Text PDFPathog Immun
March 2025
MRC Clinical Trials Unit, University College London, London, United Kingdom.
Background: In the field of tuberculosis and non-tuberculous mycobacterial (NTM) disease we are looking back on an exciting year 2024 with more than 10,000 publications listed in PubMed.
Methods: Our aim, to review the scientific literature of the year 2024, is challenged by the enormous number of publications. Therefore, if your article is not included or your favorite field of mycobacteriology not covered, please forgive us.
Tuberculosis (Edinb)
March 2025
Basil Hetzel Institute for Translational Health Research, Woodville, South Australia, Australia; Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, South Australia, Australia. Electronic address:
Animal models that can mimic progressive granulomatous pulmonary disease (PD) due to non-tuberculous mycobacteria (NTM) have not been established in rats to date. These models could assist with the study of the pathophysiology of NTM-PD as well as the preclinical development of new therapies. In the present study, an immunocompetent rat model of progressive Mycobacterium abscessus (MABs)- PD was developed using MABs originating from a patient with cystic fibrosis.
View Article and Find Full Text PDFBMC Infect Dis
March 2025
Chula Neuroscience Center, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, 10330, Thailand.
Background: Encephalitis is rarely caused by nontuberculous mycobacteria (NTM), which is generally not considered a highly virulent pathogen. However, NTM encephalitis in immunocompromised hosts occurs with varied clinical presentations, posing a diagnostic challenge in clinical practice. This study aims to describe an atypical case of NTM encephalitis caused by Mycobacterium celatum, which has not previously been reported to infect the central nervous system of immunocompromised hosts, mimicking autoimmune striatal encephalitis (ASE).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!